{"id":962143,"date":"2026-05-13T08:23:09","date_gmt":"2026-05-13T12:23:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/"},"modified":"2026-05-13T08:23:09","modified_gmt":"2026-05-13T12:23:09","slug":"candel-therapeutics-to-present-at-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/","title":{"rendered":"Candel Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEEDHAM, Mass., May  13, 2026  (GLOBE NEWSWIRE) &#8212; \u00a0Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel\u2019s President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences.<\/p>\n<p>\n        <strong>Stifel 2026 Virtual Targeted Oncology Forum<\/strong><br \/>\n        <br \/>Date\/ Time: Wednesday, May 20, 2026, at 10 AM ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cax6e7ninjGT-61l0DSD6IKt_WNr-s4G_clp_5ICZvDX-rbR-E_F0_B_4D2NruuppxsqKH-AI1NQAOr2PHJmY72dAX9uuxHl3ZngJNBFMUrsr_PM9_WkLrd0r71xaSqK1e8s5Bz1ABHC1JT8jZhOcvc_nPHx1e-0prQALTtvecQ4jO80HkbwsuNoocbxa2aOdTM50pm_9b4L3M04_gP81g==\" rel=\"nofollow\" target=\"_blank\">Stifel \/ Candel Presentation<\/a><\/p>\n<p>\n        <strong>2026 Jefferies Global Healthcare Conference (New York, NY)<\/strong><br \/>\n        <br \/>Date\/Time: Wednesday, June 3, 2026, at 5:30 PM ET<br \/>Webcast Link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ngX1qzsTiGq4uqvqJOtxH0f1zjuqsslMigNxVpWHKrDfz_zrV3Q8cZJiukWn1S4vy29ELQcr4TFKNB0rr5w5XJGCw5IQcTkTqNagUubzH5j0YqwQe2p1xYtYcKAO3ipZQ6lr3VH1k9g6D11pvh11U-nM3xhUL2G_tlhk-FfOzSH7J1Obc06kixMxIkA6rcSDzgckT0I-F9O3QjjVSVzXdQ==\" rel=\"nofollow\" target=\"_blank\">Jefferies \/ Candel Presentation<\/a><\/p>\n<p align=\"justify\">Live webcasts of the presentations will be available by selecting Events and Presentations under the News &amp; Events tab in the Investors section on www.candeltx.com. A replay of the webcasts will be archived for up to 90 days following the session date.<\/p>\n<p>\n        <strong>About Candel Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene or CAN-2409) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.<\/p>\n<p align=\"justify\">Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cT_YJIljTIqwC2s59B6JfBjJLsmR_4F7akHBxwU6f0clyWS5XpVCg3ixN6FT32XveA2i5EcopmYCdmMMdxAK_2e1p7MlTd7ZZ6MpS2pU0F-owUpKK2zXwDr-bi2TC6_vfmNwEi54mCitdMfaQSfXBccpooVjmkLYSzBofYpfxR-UW3Tz_3I3pSw8foVJCIYvn_jsJniAG93XvXiXnYJQ7Jn-Qvr64HosiLtFnf4UhbrYVR9BilrSqHInXaWmTS0qemN89Y8wRfJ0ozAfWNkFRw==\" rel=\"nofollow\" target=\"_blank\"><em>Nature<\/em><\/a><em> and\u00a0<\/em><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UCZzQIUTTnNrRtOFjsqNhyv7Qpqtp2kupc4qOwZTKS4_mGXlTe8VdepH0FD6VPo8gz0ZXCwoZy0vPEAx-Xwg5yiNtDtQirDLql01LzdaOo3uUjo46MBbkzgrgbMYXwsXH3YNbaxOvD-emUh3rIaWf0XWQUpzrwzAzI85vKVF3q9Dl21qsKb79F_9w5mlf3d65B1FLAtDE3kuv7YJocxpBz5GfzcE-qh1eCpvPSdyrwXV0maswhANFIfuqNXhuc1kT2aF-dqpuRhj2gcvTqL65KerY9HT_t5Hf_nDCDEQ-jUSqtonBHJZdV8q1gd-nrzoKGcWP319A0NQKmQ9lYcnYG1ksVoHh3dTyMwdPJcvqzo=\" rel=\"nofollow\" target=\"_blank\"><em>Science Translational Medicine<\/em><\/a>\u00a0and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel\u2019s enLIGHTEN\u2122 Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.<\/p>\n<p align=\"justify\">For more information about Candel, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Eau6TXx9mPWcGzFHa_9RhP1-v2VA8Yrc9-rvxwPBDa_H26z4alP54kBd1ie90y3Lt6fN1jPhIkIZP4RC0VZUZIxDOg2PgBblwjxxtc4aBpo=\" rel=\"nofollow\" target=\"_blank\">www.candeltx.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company\u2019s platforms, including the ability of its platforms to improve overall survival and\/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company\u2019s programs; that final data from the Company\u2019s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company\u2019s ability to efficiently discover and develop product candidates; the Company\u2019s ability to obtain and maintain regulatory approval of product candidates; the Company\u2019s ability to maintain its intellectual property; the implementation of the Company\u2019s business model, including strategic plans for the Company\u2019s business and product candidates; the impact of the Company\u2019s existing and any future indebtedness on its ability to operate its business; the Company\u2019s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company\u2019s filings with the U.S. Securities and Exchange Commission (SEC), including the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Theodore Jenkins<br \/>Vice President, Investor Relations, and Business Development<br \/>Candel Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Fas2u8oBMilaFVTThiaCc1ZRLps-8dFWJXOkbLl38H0syH5tVyn-kAlcFPTfH7a6XX0PU36UK_f3qa5MuJ2sxeHIWUMnr3T55CPI_oWTDQo=\" rel=\"nofollow\" target=\"_blank\">tjenkins@candeltx.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Ben Shannon<br \/>ICR Healthcare <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5ZOLqgvgDfRqKRwm56mlEcvu53XPqBYFRj0OpfYcSgvxSIl_nDA5QMIAZ-0NrCUqbxcYvKpfMIE1cpdWxwzS_3p7gbz6cRjgrnYNB8UgJLnNbBwAnLeROI1VsH9S5w0T\" rel=\"nofollow\" target=\"_blank\">CandelPR@icrhealthcare.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGI3ZThkOTAtMjM2NC00OTBjLThlYWMtZGY3MGIzY2YxNTMwLTExMTE3MjUtMjAyNi0wNS0xMy1lbg==\/tiny\/Candel-Therapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel\u2019s President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences. Stifel 2026 Virtual Targeted Oncology Forum Date\/ Time: Wednesday, May 20, 2026, at 10 AM ETWebcast Link: Stifel \/ Candel Presentation 2026 Jefferies Global Healthcare Conference (New York, NY) Date\/Time: Wednesday, June 3, 2026, at 5:30 PM ETWebcast Link: Jefferies \/ Candel Presentation Live webcasts of the presentations will be available by selecting Events and Presentations under the News &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Candel Therapeutics to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962143","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Candel Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Candel Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel\u2019s President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences. Stifel 2026 Virtual Targeted Oncology Forum Date\/ Time: Wednesday, May 20, 2026, at 10 AM ETWebcast Link: Stifel \/ Candel Presentation 2026 Jefferies Global Healthcare Conference (New York, NY) Date\/Time: Wednesday, June 3, 2026, at 5:30 PM ETWebcast Link: Jefferies \/ Candel Presentation Live webcasts of the presentations will be available by selecting Events and Presentations under the News &hellip; Continue reading &quot;Candel Therapeutics to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:23:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Candel Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2026-05-13T12:23:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\"},\"wordCount\":894,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\",\"name\":\"Candel Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=\",\"datePublished\":\"2026-05-13T12:23:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Candel Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Candel Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Candel Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel\u2019s President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences. Stifel 2026 Virtual Targeted Oncology Forum Date\/ Time: Wednesday, May 20, 2026, at 10 AM ETWebcast Link: Stifel \/ Candel Presentation 2026 Jefferies Global Healthcare Conference (New York, NY) Date\/Time: Wednesday, June 3, 2026, at 5:30 PM ETWebcast Link: Jefferies \/ Candel Presentation Live webcasts of the presentations will be available by selecting Events and Presentations under the News &hellip; Continue reading \"Candel Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:23:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Candel Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2026-05-13T12:23:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/"},"wordCount":894,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/","name":"Candel Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=","datePublished":"2026-05-13T12:23:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxNzc3OSM3NTk2NTA4IzIxMDAxNTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/candel-therapeutics-to-present-at-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Candel Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962143"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962143\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}